Top 5 regulatory compliance risks RA leaders can’t ignore in 2026

In 2026 we can expect regulations to change faster, and become more integrated and harmonized. For RA leaders, that means the stakes have never been higher. A missed detail could delay your launch — or trigger a recall. Here’s your quick-hit checklist of the top 5 regulatory compliance risks to watch in 2026, and what you can do now to stay ahead.

Risk 1: AI-generated content — regulatory scrutiny and oversight challenges

We’ve all encountered AI hallucination. In everyday life, it is annoying or occasionally amusing. But it’s not acceptable in the pharmaceutical and medical device sector. AI offers very many opportunities, especially because – unlike a standard search engine – it distils and crystallizes information, saving us time and legwork. And that’s also the pain point for RA teams, but. regulators demand transparency. They demand accountability and that you understand your processes. And they expect validation and audit trails, especially for AI-assisted content.

Watch out for: Lack of oversight for your AI-assisted content.

Action: Make sure you have strong human-in-the-loop processes and documentation in place.

Risk 2: global labeling convergence — accuracy, localization, and transparency

The sheer complexity and volume of regulations is a challenge. These place high demands on pharmaceutical, medical device and FMCG industries for clear, consistent labeling. The complexity is in part due to differing requirements in local markets. Accuracy is the key – and patient and consumer safety depend on it. It would be wrong to approach global and local markets as being in simple contradiction, even when regulations differ. See them in terms of integration – integrate processes that account for difference.

Watch out for: Inconsistent claims across your different markets, and any localization requirements you might be missing.

Action: Use centralized systems and automated proofreading tools to verify every version – global and local. It’s the best way to manage regulatory divergence.

Risk 3: expanding data standards — FHIR, ePI, and interoperability risks

The digital landscape is becoming even more digital by the day. That saves time and makes us more efficient. Technologies are providing new opportunities. Great. Inevitably, they are also leading to new requirements. Fast Healthcare Interoperability Resources, identification of medicinal products (IDM), electronic product information (ePI) – these are just the tip of the iceberg in a sea of change where regulatory submissions and product information are moving toward formats that are highly structured and interoperable (i.e. can be easily exchanged).

Watch out for: Mismatched formats, unverified XML/FHIR files, and data silos.

Action: Build internal expertise and test systems now to avoid compliance gaps – that way you can avoid sailing into the iceberg.

Risk 4: supply chain traceability – serialization, barcodes and anti-counterfeiting

The new frontier of compliance goes beyond your product dossier for a pharmaceutical. Today, we are entering complex territory where requirements for serialization, greater use of barcodes (i.e., for electronic labeling), and track-and-trace systems to prevent product counterfeiting are becoming even tighter. Drug counterfeiting has long been recognized as a problem with far-reaching consequences in the pharma sector. But manufacturers of FMCGs are in the field here too – financially, but also because counterfeit products generally are of inferior quality and can pose safety risks for consumers.

Watch out for: Barcodes (in their 2D and 3D formats) that are unreadable and do not comply with regulatory requirements.

Action: Fortunately, there are reliable solutions. Use them. Regularly grade your barcodes, verify them, and keep a watchful eye on how regional standards are evolving (as jurisdictions are not moving at the same pace).

Risk 5: speed vs. accuracy — balancing efficiency in regulatory submissions

There’s a classic cartoon series from Warner Bros called Road Runner. In it, a ridiculous Wile E. Coyote always chases the incredibly fast Road Runner. Coyote tries every trick and shortcut imaginable to catch Road Runner. He’s obsessed with speed, but constantly miscalculates, overshoots, or triggers his own traps. Meanwhile, Road Runner stays cool, consistent, and always one step ahead. In the race for regulatory approval, we risk being Coyote, strapping a rocket to the submission but crashing when a detail goes wrong.

The intelligent Road Runner (or its good figurative friend, the Rabbit, at Schlafender Hase) is who we want to be, especially when faced with growing pressure in 2026 to get products to market quicker. Still using manual reviews? Cutting corners and taking shortcuts in review and quality control, especially using manual processes, is hasty and high-risk. It leads to that terrible cliff face!

Watch out for: Human error in high-volume documentation reviews.

Action: Implement automation and intelligent proofreading to achieve speed, ensuring quality while you meet those deadlines.

Hopping into 2026: build resilience before risks multiply

The risks have been with us for a while now. But we can expect these risks to magnify in 2026. As an RA professional, you need to build your resilience now and be ready for the coming challenges – with stronger governance, smarter tools and better cross-industry awareness.

Do you know where the pain points and hidden risks lurk? Kick off 2026 with this knowledge in your pocket. Get in touch with us to find out how TVT will help you meet the challenges coming your way.